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ABSTRACT 
γ-Hydroxybutyric acid (GHB) is a popular drug increasingly associated to cases of 
drug-facilitated sexual assault (DFSA). Currently, expanding procedures of analysis and 
having forensic evidence of GHB intake at a long term are mandatory. Up to now, most 
studies have been performed using GC-MS and LC-MS as analytical platforms, which 25 
involve significant manipulation of the sample and, often, indirect measurements. In this 
work, procedures used in NMR-based metabolomics were applied to a GHB clinical trial on 
urine and serum. Detection, identification and quantification of the drug by NMR methods 
were surveyed, as well as the use of NMR-based metabolomics for the search of potential 
surrogate biomarkers of GHB consumption. Results demonstrated the suitability of NMR 30 
spectroscopy, as a robust nondestructive technique, to monitor (detect, identify and 
quantify) fast and directly exogenous GHB in almost intact body fluids, and its high 
potential in the search for metabolites associated to GHB intake. 
 
Keywords: GHB, γ-hydroxybutyric acid, body fluids, NMR spectroscopy, metabolomics, 35 
serum, urine, drug control. 
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Introduction 
γ-Hydroxybutyric acid (GHB)
1
 has a high impact in society as a popular substance of 
abuse associated to cases of drug-facilitated sexual assault (DFSA) - commonly referred to 40 
as “date-rape”. GHB intake produces effects such as sleep and amnesia, which render the 
victim vulnerable.
2-5
 Other misuses comprehends recreational purposes as a club drug and 
as a muscle-building supplement.
6,7
 Named after “liquid ecstasy”, illicit GHB is marketed 
mostly as the sodium salt (sodium γ-hydroxybutyrate, NaGHB), being other related 
compounds the lactone precursor γ-butyrolactone (GBL) and 1,4-butanediol (BD) which 45 
are both metabolized to GHB after ingestion. Misuse of the drug can cause serious medical 
problems including trouble breathing seizures, coma, and death.
8
 Synthetic GHB, branded 
as Xyrem®, is also a pharmaceutical with medicinal use in the treatment of narcolepsy and 
alcohol withdrawal.
9,10
 It is a highly regulated drug,
11
 requiring patient enrollment in a 
restricted access program.
12,13
 On the other hand, GHB is a naturally-occurring metabolite 50 
of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). It is primarily found in the 
brain and acts as a central nervous system depressant.
1,8
 
The growing number of sexual assault and overdose cases with the suspicion of GHB 
intake urge to adopt measures to address the problem,
14
 being mandatory improving and 
expanding current procedures for the analysis of consumed GHB, related drugs and 55 
associated metabolites in body fluids. One of the major current challenges is having 
forensic evidence of accidental (or deliberate) GHB consumption at a long term (for 
example, > 24 h after intake). The difficulty of it falls upon the rapid metabolism and 
excretion of exogenous GHB, meaning a short time detection window before concentration 
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 4 
goes back to an endogenous level (3-4 h urine and blood).
15,8
 As endogenous metabolite, 60 
GHB is present in urine and blood in much lower concentration (typically 0.2 to 1 
mg/L)
15,16
 than shortly after drug abuse. Many studies establish a cut-off discriminant limit 
(10 mg/L, 0.1 mM) to distinguish external exposure from endogenous values.
10,17,18
 The 
major pathway of endogenous GHB metabolism involves its conversion to succinic 
semialdehyde (SSA) and succinate by SSA dehydrogenase.
19,1
 Products consistent with 65 
GHB β-oxidation, including glycolic,3-oxo-4-hydroxybutyric, and 3,4-dihydroxybutyric 
acids, have been described in the urinary profile of individuals with SSA dehydrogenase 
deficiency, suggesting this metabolic route.
20,21
 Also, a recent study showed the existence 
of endogenous GHB glucoronide in urine.
22
 To present, there are just a few works 
regarding the metabolism of exogenous GHB in animal models. The rapid metabolism of 70 
GHB to succinic acid in rat after intraventricular injection has been described
23,24
 and the 
conversion of GHB to D-2-hydroxyglutaric acid in rats and baboons have been also 
reported.
25 
Most of the described studies regarding exogenous GHB in biofluids are carried out 
using procedures based on GC-MS and LC-MS as analytical platforms; also, works based 75 
on GC-FID or UV have been published.
8
 While standing out for a high sensitivity, these 
procedures involve a considerable manipulation of the original sample previous the 
analysis; for instance, drug isolation by extraction and/or chromatographic processes, drug 
conversion to a derivative or to GBL, changes in pH, in temperature, etc.
8,26
 Sample 
manipulation favours the loss of significant information of the original biological matrix 80 
and the introduction of errors in the measurement. As well, most of the described methods 
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 5 
do not allow distinguishing between GHB, GBL or BD by the same analysis, a matter of 
interest in some forensic cases.
27
 Finally, many of these procedures end with the destruction 
of the sample, preventing further analyses. In this context, NMR spectroscopy is a powerful 
tool for body fluid profiling
28
 with many inherent advantages; such as minimal sample 85 
preparation, no sample destruction, simple experimental setup and nonequilibrium 
perturbing. It allows the absolute quantification of compounds in a straightforward way, 
using an internal reference or an ERETIC (electronic reference to access in vivo 
concentrations)
29
 signal, with no need of calibration standards curves.
30
 Also, it allows to 
follow various biochemical responses, without a preselection of metabolites, observing the 90 
response of the whole mixture. To our knowledge, only one study of ingested GHB through 
NMR spectroscopy has been reported - a clinical trial of the drug on saliva.
31
 Apart from it, 
a few works of pure GHB and GBL in water and a study of spiked GHB in some body 
fluids have been carried out using NMR spectroscopy.
32-34
 
With the present study, we aimed to explore the feasibility and suitability of NMR 95 
spectroscopy to monitor exogenous GHB in body fluids. To this end, a NMR-monitored 
clinical trial of exogenous GHB on urine and serum was carried out for the first time, and 
different NMR analyses were assessed. Detection, identification and quantification of the 
drug within biological matrices were evaluated, as well as the potential of NMR-based 
metabolomics in the search for surrogate biomarkers indicative of drug consumption.
35,36
 100 
With this approach, we aim to facilitate and accelerate the analysis of exogenous GHB in 
body fluids by the use of different NMR-based methodologies, as well as to advance in the 
search of long term forensic evidence of GHB using a metabolomics-based approach. 
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Experimental Section 105 
Reagents and Chemicals 
Glycolic acid, succinic acid, 3-(trimethylsilyl)-[2,2,3,3-
2
H4]-propionic acid sodium 
salt (TSP), sodium dihydrogen phosphate, disodium hydrogen phosphate and sodium azide 
were purchased from Sigma-Aldrich S.A. (Tres Cantos, Madrid, Spain). Deuterium oxide 
(99.96 % D) was obtained from Cortecnet (Voisins-le-Bretonneux, France). Serum tubes 110 
(Vacutainers
TM
, 8mL) were purchased from MidMeds (Essex, U.K.). 
 
Experimental Design 
Ethical approval for the GHB administration study was obtained from the research 
ethics committee of the King’s College London Drug Control Centre (approval number 115 
CREC/06/07-30). Written informed consent was obtained from twelve volunteers (six men 
and six women). Males had a mean age of 25 years (21–36 years) and a mean body mass 
index (BMI) of 23.7 kg/m
2
 and females had a mean age of 26 years (22–32 years) and BMI 
of 23.0 kg/m
2
. Prior to the study, volunteers were assessed to be in good health. Exclusion 
criteria included a history of liver disease, succinic semi-aldehyde dehydrogenase 120 
deficiency, and currently breast feeding. All volunteers tested negative for the current use 
of sedatives, recreational drugs, and pregnancy (females only). A single dose (25 mg/kg 
body weight) of GHB was administered in the form of Xyrem® (sodium oxybate, 500 
mg/L). Urine and blood samples were taken before and at different times after dose (see 
Brailsford et al. for further details).
15
 Urine samples at time points -10 min, 1, 2, 4, 6, 14, 125 
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 7 
20, 24 and 30 h post-dose were analyzed. Serum samples at time points -10 min. and 1 h 
post-dose were analyzed. 
 
Sample Collection, Storage and Preparation 
For serum collection, 10 mL of whole blood was allowed to clot for 30 min in the 130 
Vacutainer
TM
 in which it was collected. Each sample was centrifuged (1000 g, 10 min) and 
the supernatant (serum) was transferred into a polypropylene tube. A 0.5 mL aliquot of 
each sample was lyophilized and the dried material was storage at -80⁰C until analysis. For 
urine samples, the volunteers were asked not to void any urine at times other than those 
specified up to 24 h post-administration. A single spot urine was collected at 30 h. Samples 135 
were centrifuged (16000 g, 10 min), aliquoted (1.8 mL) and lyophilized. The dried material 
was storage at -80⁰C until analysis. Prior to the analysis each sample was reconstituted in 
D2O (0.45 mL for serum and 0.9 mL for urine) without observing any precipitate. NMR 
samples were prepared mixing 400 µL of the reconstituted sample with 200 µL of a sodium 
phosphate buffered stock solution (0.2 M in D2O, pH 7.4, containing 1 mM of TSP and 3 140 
mM of NaN3) directly in the 5mm NMR tube. 
 
NMR Spectroscopy 
NMR experiments were carried out on a Bruker AVANCE II 600 spectrometer 
operating at 14.1 T (600.13 and 150.92 MHz, 
1
H and 
13
C frequencies respectively), fitted 145 
with a 5mm multinuclear triple resonance (TBI) probe, a z-axis pulsed field gradient, an 
automatic sample changer and a temperature control unit (Bruker BioSpin, Rheinstetten, 
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 8 
Germany). The probe temperature was maintained at 298.0 K for all experiments. Sample 
handling, automation, acquisition and processing were controlled using the software 
TOPSPIN 3.1 (Bruker BioSpin, Rheinstetten, Germany). 150 
For urine samples 1D 
1
H NMR experiments were performed using the pulse sequence 
1D NOESY-presat.
37
 For serum samples a standard CPMG (Carl-Purcell-Meiboom-Gill) 
spin-echo sequence
38
 with presaturation of the residual water signal was used. In both 
cases, data were collected into 32 K data points during an acquisition time of 1.7 s and 
using a relaxation delay (RD) of 3 s. Spectra were recorded in the time domain as 155 
interferograms (FID) across a spectral width of 9615 Hz and as the sum of 128 transients. 
FIDs were automatically Fourier transformed and the spectra were phased, baseline 
corrected and referenced. 
2D experiments, 
1
H-
1
H COSY (Correlated Spectroscopy), 
1
H-
1
H TOCSY (Total 
Correlation Spectroscopy), 
1
H-
13
C HSQC (Heteronuclear Single Quantum Coherence) and 160 
1
H-
13
C HMBC (Heteronuclear Multiple Bond Correlation), and 1D 
1
H selective TOCSY 
experiments were acquired using standard Bruker pulse sequences and routine conditions. 
1D 
1
H qNMR experiments were performed using a standard 90° pulse-acquisition 
sequence with presaturation of the residual water signal. Data were recorded using the same 
parameters described before; except for an RD of 15 s. GHB and TSP integration and 165 
quantification was performed with MestreNova 8 (Mestrelab Research S.L.) and its global 
spectral deconvolution (GSD) application. 
NMR data acquisition for the metabolomic study on urine was conducted through 1D 
1
H NMR spectroscopy measurements, using the 1D 
1
H NOESY-presat experiment with the 
acquisition and processing parameters described before. All experiments were performed 170 
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 9 
under automatized identical conditions. The temperature into the probehead was previously 
calibrated and maintained constant at 298.0 K. For this purpose, an equilibration delay (2 
min) was left once the tube was into the magnet and prior to the shimming process in all 
analyses. After acquisition, resulting FIDs were automatically Fourier transformed, spectra 
were phased, baseline corrected and referenced. The FIDs were multiply by an exponential 175 
apodization function equivalent to 0.2 Hz of line broadening prior to the Fourier transform. 
The phase and baseline corrections and the calibration of all spectra were checked manually 
after the automatic process. The total experimental time was ca. 8 min per sample. 
All spectra were referenced to the TSP peak resonance at (δH and δC at 0.00 ppm). 
 180 
Statistical Analysis 
For the statistical analysis, spectra were normalized to total intensity to avoid the 
influence of differences in sample concentration, and submitted to variable size bucketing. 
Bucket tables were then pareto scaled, to better take into account the variation of the small 
peaks, and mean centered. Orthogonal partial least squares discriminant analysis (OPLS-185 
DA)
39
 was performed in SIMCA 14 (Umetrics). Models were validated with Anova cross-
validation and permutation. Random forests analysis
40
 and significance analysis of 
metabolites (SAM)
41
 were performed with Metaboanalyst.
42
 Random forests were 
performed with 1000 trees and 7 predictors per node. SAM analysis was based on the FDR 
and q-value method.
43
 The identification of glycolate and succinate was done by reference 190 
to reported data
44
 and confirmed by standard addition (“spiking” the sample). 
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 10 
 
Results and Discussion 
A study based on NMR spectroscopy of body fluids urine and serum of twelve 195 
healthy sex-matched volunteers having consumed GHB was conducted for the first time. 
Considering the reported data regarding GHB dosage as a pharmaceutical and GHB 
consumption as an illicit drug,
8
 a single low dose of GHB was given to each volunteer (25 
mg/Kg, total amount ranging from 1.4 to 2.6 g). The administered concentration was in the 
low dosage range of reported clinical studies (25 to 72 mg/Kg).
15
 Samples were collected 200 
before (-10 min) and at several time points after drug administration (up to 30 h and 13 h 
for urine and blood respectively). Procedures described at NMR-based metabolomics were 
followed in the sample preparation (Experimental section). For practical reasons, samples 
were lyophilized and later reconstituted in half the original volume of D2O, resulting in a 
two-folded original concentration. However, depending on the case of study, the sample 205 
should not be necessarily lyophilized neither concentrated, speeding up the sample 
preparation process.
37 
 
Monitoring exogenous GHB: detection and identification in urine and serum 
The first goal consisted in observing if the drug at the concentration administered was 210 
NMR-detectable using metabolomics standard conditions, in post-dose urine and serum; i.e. 
directly in the biological matrix and with minimum manipulation. To our knowledge, there 
is no reported example of this nature up to date. Samples of all twelve volunteers before (-
10 min) and after (1 h) drug intake were analyzed by a standard 1D 
1
H NMR experiment 
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and the resulting spectra were compared. In the case of urine, a 
1
H NOESY-presat 215 
experiment was acquired, while for serum a CPMG-presat experiment was recorded in 
order to minimize the contribution from macromolecules (proteins and/or lipids). Every 
experiment took ca. 8 min to perform, being the sample afterwards in perfect conditions to 
conduct further analyses. The comparison of pre-dose and post-dose urine spectra revealed 
the presence of three signals at chemical shifts, δH, 1.80, 2.24 and 3.60 ppm detectable only 220 
in post-dose samples, which corresponded to δH previously described for GHB.
31-34,45
 
Analogous results were obtained for serum. Results showed that, using standard 
1
H NMR 
metabolomics conditions, the drug was quickly detected whereas GHB at an endogenous 
concentration was not. As an example, Figure 1 shows urine and serum spectra of a 
volunteer. 225 
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Figure 1. 
1
H NMR spectra of body fluids from a same healthy volunteer before (-10 min) 
and after (1 h) GHB administration. a) Pre-dose and b) post-dose serum CPMG-presat 
spectra; c) pre-dose and d) post-dose urine NOESY-presat spectra. Experiments performed 
at a magnetic field of 600.13 MHz and at 298.0 K of temperature. 230 
 
After that, a complete 
1
H and 
13
C NMR analysis of GHB by standard 1D and 2D 
NMR experiments was performed in both biofluids, with the aim to identify 
1
H and 
13
C 
NMR signals of the molecule and their coupling patterns within urine and serum matrices. 
Representative samples at 1 h post-dose were selected. Homonuclear and heteronuclear 2D 235 
NMR experiments, 
1
H-
1
H COSY, 
1
H-
1
H TOCSY, 
1
H-
13
C HSQC and 
1
H-
13
C HMBC, and 
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1D selective TOCSY experiments were recorded. GHB
 1
H and 
13
C signals were identified 
clearly in both matrices. As an example, Figure 2 presents some of the results obtained for 
urine. The signal corresponding to protons H3 of GHB consisted on an isolated peak (a 
triplet of triplets) at 1.80 ppm. When H3 was selectively irradiated via 1D 
1
H selective 240 
TOCSY, a clean filtered spectrum of GHB resulted (Figure 2a). This is a helpful 
experiment to quickly confirm the presence of the drug within complex matrices, which can 
be also used for quantification.
46
 By the 
1
H-
1
H COSY experiment (Figure 2b) the 
1
H-
1
H 
correlation pattern of GHB was clearly observed. Figure 2c shows 
1
H-
13
C HSQC with the 
one-bond 
1
H-
13
C coupling pattern highlighted. In the 
1
H-
13
C HSQC correlation the 245 
unfolding of 
1
H signals in the 
13
C second dimension occurs, favoring the enhancement of 
spectral dispersion due to the broader chemical shift range of 
13
C compared to 
1
H. 
1
H-
13
C 
HSQC represents a useful alternative to 1D 
1
H and 2D 
1
H-
1
H experiments when these are 
not enough for the identification of the drug in the biological sample due to severe signal 
overlapping.
47
 Values of δH and δC of GHB detected in urine and serum (pH 7.4, 298.0 K) 250 
are gathered in Figure 2d. Remaining correlations of urine, analogous spectra of serum and 
of pure GHB are in the Supporting Information (Figure S1 to Figure S3). 
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 255 
Figure 2. Selected areas of a) 1D 
1
H selective TOCSY with saturation of H3 signal at 1.80 
ppm; b) 
1
H-
1
H COSY and c) 
1
H-
13
C HSQC from a representative 1 h post-dose urine 
sample. d)
 1
H and 
13
C NMR characterization of GHB in urine and serum (pH 7.4, 298.0 K). 
Spectra recorded at a magnetic field of 600.13 MHz. 
 260 
In all examples shown in this work GHB is present in the carboxylate form since the 
pH was adjusted to 7.4 (GHB pKa 4.71). However, NMR could distinguish the form of 
GHB in the sample (as a free acid, as a carboxylate or a mixture of both) and the 
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quantification of the ratio when an equilibria between the two species exist; in that case 
experiments must be done preserving the original ratio without adjusting the original pH.
32
 265 
 
Quantifying exogenous GHB in urine by 
1
H qNMR 
The direct quantification of GHB in urine after consumption using NMR 
spectroscopy was assessed in a specific example. Using the samples of the experiment 
described, the pharmacokinetics of GHB in urine was monitored through 
1
H qNMR 270 
(quantitative NMR) as an example of the direct quantification of the drug within a body 
fluid. Results obtained were compared with previous ones –(performed with aliquots of the 
same original samples) obtained from a well stablished indirect analysis of GHB by a GC-
MS based procedure.
15
 
Samples at time points -10 min, 1, 2, 4 and 6 h post-dose were analyzed. As in the 275 
previous section, minimum sample preparation was needed, consisting mainly on the 
addition of a stock buffered D2O solution in the reconstituted urine aliquot. The stock 
solution contained internal reference, TSP, of known concentration, to be used as internal 
standard for quantification. All samples were analyzed using a 1D 
1
H qNMR experiment 
with suppression of the residual water signal. The same acquisition and processing 280 
parameters than in a standard 1D proton experiment were applied, except for a longer 
relaxation delay allowing all signals to completely relax in order to provide quantitative 
data (Experimental Section). GHB H3 signal (1.80 ppm) and TSP singlet (0.00 ppm) were 
integrated in all spectra after deconvolution of the peaks, avoiding errors due to possible 
low intensity overlapped signals and base line effects. The concentration of GHB in the 285 
original urine samples of each volunteer was calculated using TSP as internal standard, 
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applying the corresponding volume correction factor according to sample preparation and 
considering that H3 signal corresponds to two protons of the GHB molecule and TSP 
singlet to 9 protons of the TSP compound. GHB eliminated amount in each urinary void 
was calculated considering the total collected volume. After that, average values of 290 
concentration and eliminated amount at each time point were calculated (Supporting 
Information, Table S1). Plots of concentration and eliminated amount vs time are shown in 
Figure 3a and Figure 3b respectively. Profiles of maximum and minimum values are also 
plotted. The maximum concentration of GHB occurred at first post-dose collection (1 h), 
the mean value being 55.5 mg/L, ranging from 24.6 to 113.4. After 2 h, the mean 295 
concentration decreased significantly to 37.9 mg/L. After 4 h, GHB was just detected in 
one of the twelve samples (8.4 mg/L). After 6 h GHB was not detected in any volunteer’s 
urine. As expected, curves of eliminated amount vs time presented an analogous profile. 
After 1 h, the mean GHB eliminated was 14.0 mg (ranging from 1.8 to 22.5). After 4 h, the 
mean eliminated amount was 8.2 mg.
 1
H qNMR results were in accordance with those 300 
reported by Brailsford et al.,
15
 in which aliquots of the same sample pool were analyzed. In 
that work, a wide pharmacokinetic study of GHB in different body fluids including urine 
was carried out. A procedure based on GC-MS analysis was used, where GHB was initially 
converted into GBL by the acidification of the sample and then a liquid-liquid extraction 
was carried out prior to the analysis. In that study a Tmax of 1 h, a Cmax of 67.6 mg/L and 305 
similar pharmacokinetic profiles (after 4 h GHB concentration were at an endogenous 
level) were obtained. Our results are also within the same range of other published data.
15 
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Figure 3. Pharmacokinetics of exogenous GHB in urine
 
monitored by
 1
H qNMR 310 
experiments. a) GHB concentration and b) GHB eliminated amount curves over time; 
profiles for mean (12 volunteers), maximum and minimum values. 
 
The fact that H3 signal of GHB is nicely isolated in the proton spectrum, with 
minimum overlap, facilitates the quantification of the compound directly in the mixture by 315 
1D 
1
H qNMR. Alternatively, when situations of severe signal overlap, 2D NMR 
quantitative methods could yield accurate quantitative results.
48
 In the present work, each 
1D quantitative experiment took ca. 30 min, being the sample afterwards in perfect 
conditions to conduct further analyses. In turn, the quantification of exogenous GHB in 
serum samples could be carried out analogously by 1D 
1
H qNMR experiments. In this case, 320 
the use of ERETIC
29
 as reference for quantification would be recommended due to the 
possible presence of protein, which could bind the internal reference (TSP) and its signal 
would not be reliable for quantification. Using standard conditions and equipment of 
1
H 
NMR-based metabolomics (128 transients, 600 MHz magnet and a conventional probe), 
endogenous concentration levels of GHB were not detected. Endogenous concentrations 325 
Page 17 of 28
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 18 
may vary from 0.2 to 1 mg/L; a discriminant limit of 10 mg/L (ca. 0.1 mM) has been 
defined to distinguish external exposure from endogenous values.
15-18
 With standard 
equipment for metabolomic studies (typically 500-600 MHz magnets with cryo- or 
conventional probes) concentrations up to the 0.1 mM could be detected and quantified.
48
 
Lower detection and quantification limits can be reached using more advance equipment, 330 
i.e. higher field magnets (up to 1 GHz available), cryogenically cooled probes and/or small-
volume microprobes (60 µL).
30
 The sensitivity of NMR spectroscopy (and therefore the 
detection limit for GHB quantification) depends strongly on different aspects related to the 
equipment used (magnetic field, room temperature or cryogenic probe, 5 mm or 3 mmm 
probe, etc.), the nucleus observed and the experiment acquired.
49 
335 
 
 
Search of metabolites associated to GHB consumption by NMR-based metabolomics 
After proving that exogenous GHB within urine or serum matrices can be directly 
monitored by NMR spectroscopy, the suitability of the technique in the search of 340 
metabolites associated to GHB consumption using a metabolomics approach was assessed. 
The specific goal was to explore, by untargeted NMR-based metabolomics, the detection of 
any eventual metabolite in the biofluid with an altered concentration due to GHB ingestion; 
and in that case, explore its potential use as a surrogate biomarker for forensic evidence of 
GHB consumption at a long term. The study was performed in urine as model biofluid, due 345 
to its easy accessibility and manipulation compare to serum.
15
 Metabolic profiling in 
combination with multivariate analysis was performed in samples collected at -10 min, 1 h 
and 20 h after GHB administration. 
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 19 
Initially, pre-dose (-10 min) and 1 h post-dose samples were compared by orthogonal 
partial least squares discriminant analysis (OPLS-DA). A robust model was obtained 350 
where, as expected, GHB peaks (1.80, 2.34 and 3.60 ppm) were identified as the main 
discriminant signals in the corresponding S-plot (Figure 4a). Interestingly, another feature, 
a singlet at 3.94 ppm, stood out for its high significance in the discrimination of the two 
groups. The signal was initially identified as glycolate,
50
 based on the δH and the δC (63.9 
ppm) values and prior reported data;
44
 the δC was obtained via an 
1
H-
13
C HSQC experiment 355 
recorded on a representative sample of the pool. The assignment was unambiguously 
confirmed by a subsequent standard addition (‘spiking’) of glycolate in the sample. The 
next significant discriminant feature corresponded to signal at 2.41 ppm, identified as 
succinate.
51
 The same procedure described before was followed for the identification of 
succinate.
44
 Another discriminant feature corresponded to peak at 4.05 ppm, identified as 360 
creatinine.
52
 Results showed that, as for GHB, concentrations of glycolate and succinate 
increased after 1 h of drug ingestion, while for creatinine the behavior was the opposite. 
The relevance of glycolate and succinate features for group separation was further 
confirmed by SAM (significance analysis of metabolites) and random forests analysis, were 
they scored within the five metabolites with highest variable importance. After that, pre-365 
dose (-10 min) and 20 h post-dose samples were compared. In the resulting OPLS-DA 
model, glycolate was still identified among the relevant metabolites in the S-plot, together 
with creatinine. Succinate was not detected as discriminant any more and, as expected, 
GHB neither (Figure 4b). As well, these results were confirmed by SAM and random 
forests modelling. 370 
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Figure 4. Urine OPLS-DA score plot and S-plot from 
1
H metabolic profiles of samples 
before and after GHB intake. A) Comparison of -10 min pre-dose and 1 h post-dose 375 
samples; 1+1 components; R2Y(cum) = 0.93, Q2(cum) = 0.75, CV-Anova = 0.00016. b) 
Comparison of -10 min pre-dose and 20 h post-dose samples; 1+2 components; R2Y(cum) 
= 0.93, Q2(cum) = 0.65, CV-Anova = 0.004. 
 
Both, succinate and glycolate have been previously associated to the metabolism of 380 
endogenous GHB. Primarily, endogenous GHB is metabolized to succinic acid via 
oxidation of the intermediate succinic semialdehyde (SSA) by SSA dehydrogenase.
20
 In the 
case of individuals with SSA dehydrogenase deficiency, GHB is metabolized to glycolic 
acid via 3,4-dihydorxybutyric acid intermediate.
21
 The present study, through NMR-based 
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untargeted metabolomics, showed that the concentrations of succinate and glycolate in 385 
urine increased significantly after GHB consumption. Results suggested that exogenous 
GHB (or a fraction of it) is metabolized to succinate and glycolate, which coincides with 
the observed in the metabolism of endogenous GHB. No presence of GHB glucoronide was 
observed, neither as a discriminant feature nor in a detailed analysis of 1D and 2D NMR 
spectra of a representative sample at time point 1 h post-dose.
22
 The high sensitivity of 390 
creatinine concentration in urine to factors like circadian rhythm or diet
53
 made difficult to 
state a direct correlation between GHB ingestion and creatinine concentration just based on 
this experiment. Figure 1 indicates the signals of glycolate and succinate in the 
1
H NMR 
spectra of urine. 
At that point, the evolution of the normalized relative concentrations of glycolate and 395 
succinate in urine over time (at -10 min, 1, 2, 6, 14, 20, 24, 30 h post-dose) was studied in 
order to assess the potential use of them as surrogate biomarkers of GHB consumption at a 
long term. For that, samples at the aforementioned time points were analyzed by
1
H qNMR 
experiments. The concentration of GHB was also monitored and compared to the others. 
Figure 5 shows the normalized relative concentration profiles of the three compounds over 400 
time. As shown, while GHB and succinate concentrations dropped rapidly to an 
endogenous level (at time point 6 h), glycolate concentration decreased much slower, and 
even after 24 h a small difference can be observed. According to these results, glycolate - 
with a longer detection time window that exogenous GHB – could be an interesting 
candidate of surrogate biomarker; further targeted studies will be needed to validate its real 405 
use. To our knowledge, this is the first time that an untargeted study on the metabolism of 
ingested GHB has been carried out through NMR spectroscopy. 
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Figure 5. Boxplots of GHB, glycolate and succinate normalized relative concentrations at 410 
different time points. P-values from ANOVA are indicated. 
 
 
Conclusions 
The present work demonstrated the feasibility of NMR spectroscopy to monitor 415 
exogenous GHB in body fluids such as urine and serum. Unlike current procedures for the 
analyses of consumed GHB (mostly based on GC-MS and LC-MS), NMR spectroscopy 
allowed the quick monitoring of exogenous GHB within the almost intact body fluid, it 
yielded simultaneous interesting information of the complete matrix and it would allow to 
distinguish between GHB and associated drugs (GBL and BD) by the same analysis. Also, 420 
the non-destructive nature of the technique makes it compatible with further posterior 
analyses. The suitability of the drug detection, identification and quantification within the 
biological matrix and through the most appropriate NMR experiment was proved. Standard 
1D 
1
H NOESY-presat and CPMG-presat experiments allowed monitoring exogenous GHB 
Page 22 of 28
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 23 
in urine and serum respectively, while 2D NMR correlations and 1D selective experiments 425 
allowed the unambiguous identification of exogenous GHB in both body fluids. 
1
H qNMR 
applied to the direct quantitative analysis of GHB in urine in a pharmacokinetic study 
yielded similar results to those obtained by an indirect GC-MS procedure. The great 
potential of NMR-based metabolomics in the search of surrogate biomarkers to provide 
forensic evidence of GHB consumption at a long term was demonstrated. A significant 430 
increase of the concentration of glycolate and succinate in urine after GHB ingestion was 
proved, being glycolate an interesting candidate for further studies due to its longer 
detection time window compared to GHB and succinate. We think that these features will 
open up new interesting possibilities in future studies, complementing current procedures. 
 435 
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